Lack of Access to Clinical Trials
Minorities are less likely to enroll in studies
Only 5% of participants in Breast and Prostate Cancer prevention trials were minorities
Between 1996 to 2002, the annual number of trial participants increased from 8,000-12,000 while minority participation decreased
Clinical trials are a vital part of the biomedical research cycle because they establish whether or not new cancer treatments are safe and effective for the patients who need them. Therefore, it is imperative that participants in clinical trials that are testing new cancer treatments represent the entire population who may use them if they are approved. Despite this knowledge, participation in cancer clinical trials is low, and there is a serious lack of racial and ethnic diversity among those who do participate. It is imperative that we overcome the many barriers to clinical trial participation if we are to ensure that all segments of the population benefit from progress in the fight against cancer.
Some clinical trials are only available in major cities and require substantial travel for patients; 40% of patients drive more than 60 minutes one way.